Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Long-acting beta-2 adrenergic agonist sympathomimetic with properties similar to salbutamol.
Indicated in the treatment of asthma.
Inhaled administration.
At the date of the last update, the authors did not find any published data on its excretion in breast milk.
Its very wide volume of distribution (Boehringer 2020 and 2019) and the fact that, after inhalation, it reaches very low or undetectable plasma concentrations, (Wang 2020, Ichinose 2015) making it very unlikely that significant amounts will pass into breast milk.
Its almost zero absorption and oral bioavailability (Boehringer 2020 and 2019) makes it difficult for it to pass to the infant plasma from ingested breast milk.
Experts and scientific societies consider the use of inhaled adrenergic agonists to be low risk during breastfeeding (Lactmed, Amir 2011, National Asthma Education 2004).